Citations (23)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (1)
Gines Escolar, Xavier Carne & Eduardo Arellano-Rodrigo. (2015) Dosing of rivaroxaban by indication: getting the right dose for the patient. Expert Opinion on Drug Metabolism & Toxicology 11:10, pages 1665-1677.
Read now
Read now
Articles from other publishers (22)
Ping-Yen Liu, Eue-Keun Choi, Tae-Seok Kim, Jen-Yuan Kuo, Jung Myung Lee, Young Keun On, Sang-Weon Park, Hyung-Wook Park, Dong-Gu Shin, Lili Wang, Hsueh-Wei Yen & Moon-Hyoung Lee. (2022) XaMINA: A Real-World, Prospective, Observational Study of Treatment-Naïve Patients Treated with Rivaroxaban for Stroke Prevention in Atrial Fibrillation in Asia. Advances in Therapy 39:7, pages 3316-3333.
Crossref
Crossref
N. V. Bakulina, S. V. Tikhonov, N. B. Lishchuk & A. B. Karaya. (2021) Management of risk factors for gastrointestinal bleeding in patients receiving anticoagulant therapy. Russian Journal of Cardiology 26:8, pages 4635.
Crossref
Crossref
A. John Camm, Pierre Amarenco, Sylvia Haas, Miriam Bach, Paulus Kirchhof, Silvia Kuhls, Marc Lambelet & Alexander G.G. Turpie. (2020)
Impact of gender: Rivaroxaban for patients with atrial fibrillation in the
XANTUS
real‐world prospective study
. Clinical Cardiology 43:12, pages 1405-1413.
Crossref
Crossref
Jan Beyer-Westendorf, A. John Camm, Keith A. A. Fox, Jean-Yves Le Heuzey, Sylvia Haas, Alexander G. G. Turpie, Saverio Virdone & Ajay K. Kakkar. (2019) International longitudinal registry of patients with atrial fibrillation and treated with rivaroxaban: RIVaroxaban Evaluation in Real life setting (RIVER). Thrombosis Journal 17:1.
Crossref
Crossref
Raffaele De Caterina, Peter Kelly, Pedro Monteiro, Jean Claude Deharo, Carlo de Asmundis, Esteban López-de-Sá, Thomas W. Weiss, Johannes Waltenberger, Jan Steffel, Joris R. de Groot, Pierre Levy, Ameet Bakhai, Wolfgang Zierhut, Petra Laeis, Michael Kerschnitzki, Paul-Egbert Reimitz & Paulus Kirchhof. (2019) Characteristics of patients initiated on edoxaban in Europe: baseline data from edoxaban treatment in routine clinical practice for patients with atrial fibrillation (AF) in Europe (ETNA-AF-Europe). BMC Cardiovascular Disorders 19:1.
Crossref
Crossref
Pierre Amarenco, Sylvia Haas, Susanne Hess, Paulus Kirchhof, Marc Lambelet, Miriam Bach, Alexander G G Turpie & A John Camm. (2019) Outcomes associated with non-recommended dosing of rivaroxaban: results from the XANTUS study. European Heart Journal - Cardiovascular Pharmacotherapy 5:2, pages 70-79.
Crossref
Crossref
Alexander C. FanaroffE. Magnus Ohman. (2019) Non–Vitamin K Antagonist Oral Anticoagulants in the Treatment of Atrial Fibrillation. Annual Review of Medicine 70:1, pages 61-75.
Crossref
Crossref
Carlos Arturo Areán Martínez, Fernando Lanas, Ghazi Radaideh, Suleiman M. Kharabsheh, Marc Lambelet, Marco Antonio Lavagnino Viaud, Naser Samih Ziadeh & Alexander G.G. Turpie. (2018) XANTUS-EL: A real-world, prospective, observational study of patients treated with rivaroxaban for stroke prevention in atrial fibrillation in Eastern Europe, Middle East, Africa and Latin America. The Egyptian Heart Journal 70:4, pages 307-313.
Crossref
Crossref
Young‐Hoon Kim, Jaemin Shim, Chia‐Ti Tsai, Chun‐Chieh Wang, Gilbert Vilela, Sombat Muengtaweepongsa, Mohammad Kurniawan, Oteh Maskon, Hsu Li Fern, Thang Huy Nguyen, Thititat Thanachartwet, Kenneth Sim & A. John Camm. (2018) XANAP: A real‐world, prospective, observational study of patients treated with rivaroxaban for stroke prevention in atrial fibrillation in Asia. Journal of Arrhythmia 34:4, pages 418-427.
Crossref
Crossref
Paulus Kirchhof, Ghazi Radaideh, Young-Hoon Kim, Fernando Lanas, Sylvia Haas, Pierre Amarenco, Alexander G.G. Turpie, Miriam Bach, Marc Lambelet, Susanne Hess & A. John Camm. (2018) Global Prospective Safety Analysis of Rivaroxaban. Journal of the American College of Cardiology 72:2, pages 141-153.
Crossref
Crossref
A John Camm, Alexander G G Turpie, Susanne Hess, Pierre Amarenco, Marc Lambelet, Sylvia Haas, Martin van Eickels & Paulus Kirchhof. (2018) Outcomes after catheter ablation and cardioversion in patients with non-valvular atrial fibrillation: results from the prospective, observational XANTUS study. EP Europace 20:6, pages e87-e95.
Crossref
Crossref
Satoshi Ogawa, Kazuo Minematsu, Takanori Ikeda, Takanari Kitazono, Jyoji Nakagawara, Susumu Miyamoto, Yuji Murakawa, Yohei Ohashi, Makiko Takeichi, Yutaka Okayama, Satoshi Yamanaka & Lyo Inuyama. (2018)
Design and baseline characteristics of the Xarelto Post‐Authorization Safety & Effectiveness Study in Japanese Patients with Atrial Fibrillation (
XAPASS
)
. Journal of Arrhythmia 34:2, pages 167-175.
Crossref
Crossref
R. Pisters, S. P. G. van Vugt, M. A. Brouwer, A. Elvan, W. L. ten Holt, P. A. G. Zwart, P. Kirchhof, H. J. G. M. Crijns & M. E. W. Hemels. (2017) Real-life use of Rivaroxaban in the Netherlands: data from the Xarelto for Prevention of Stroke in Patients with Atrial Fibrillation (XANTUS) registry. Netherlands Heart Journal 25:10, pages 551-558.
Crossref
Crossref
Sui Huang, Liang Tang & Yu Hu. (2017) Present status and future orientation of rivaroxaban application in patients with nonvulvular atrial fibrillation. Thrombosis Research 156, pages 191-192.
Crossref
Crossref
Ken Okumura, Masatsugu Hori, Norio Tanahashi & A. John Camm. (2017) Special considerations for therapeutic choice of non-vitamin K antagonist oral anticoagulants for Japanese patients with nonvalvular atrial fibrillation. Clinical Cardiology 40:2, pages 126-131.
Crossref
Crossref
A. John Camm, Pierre Amarenco, Sylvia Haas, Susanne Hess, Paulus Kirchhof, Silvia Kuhls, Martin van Eickels & Alexander G.G. Turpie. (2016) XANTUS: a real-world, prospective, observational study of patients treated with rivaroxaban for stroke prevention in atrial fibrillation. European Heart Journal 37:14, pages 1145-1153.
Crossref
Crossref
Jan Beyer-Westendorf, A. Camm, Craig Coleman & CAPT Tamayo. (2017) Rivaroxaban real-world evidence: Validating safety and effectiveness in clinical practice. Thrombosis and Haemostasis 116:S 02, pages S13-S23.
Crossref
Crossref
María Monteagudo, Eva Fernández-Díaz, Jorge García-García, Óscar Ayo-Martín, Francisco Hernández-Fernández & Tomás Segura. (2015) Efficacy, safety and tolerability of rivaroxaban for the secondary prevention of stroke in patients with atrial fibrillation in clinical practice. Future Neurology 10:6, pages 529-536.
Crossref
Crossref
John Camm. (2015) International, Large-Scale, Real-World Clinical Data Confirm the Safety Profile of Rivaroxaban. EMJ Cardiology, pages 82-88.
Crossref
Crossref
Luís Mont, Francisco Marín, Fernando García-Bragado Dalmau, Marianela Sánchez Martínez & Jaime Gallego Cullere. (2015) Clinical development of rivaroxaban: emerging new clinical evidences?. Future Cardiology 11:5, pages 565-583.
Crossref
Crossref
Jan Beyer-Westendorf, Sylvia Haas & Alexander G.G. Turpie. (2015) Continued commitment to safety: building on the existing rivaroxaban knowledge base: Table 1. European Heart Journal Supplements 17:suppl D, pages D21-D28.
Crossref
Crossref
Masaharu Akao, Jan Beyer-Westendorf, Shinya Goto & Eric Peterson. (2015) Stroke prevention in atrial fibrillation: evidence from real-life studies: Table 1. European Heart Journal Supplements 17:suppl D, pages D42-D52.
Crossref
Crossref